期刊文献+

纤溶酶原激活物抑制物-1在肺血栓栓塞症、肺纤维化、支气管哮喘中的作用研究进展 被引量:5

Research progress on effect of plasminogen activator inhibitor-1 on pulmonary thromboembolism, pulmonary fibrosis,and bronchial asthma
原文传递
导出
摘要 纤溶酶原激活物抑制物-1是丝氨酸蛋白酶抑制剂家族成员之一,是纤溶酶原激活物快速、专一、有效的生理抑制剂,可影响由组织型纤溶酶原激活物参与的纤溶过程,以及尿激酶型纤溶酶原激活物参与的生理病理条件下纤维蛋白溶解、细胞外基质循环、细胞迁移、组织修复、肿瘤浸润及转移等过程。 Plasminogen activator inhibitor-1 (PAI-1) is one of the members of the family of serine protease inhibitors, is fast, specific, effective physiological inhibitor of plasminogen activator, can affect process of fibrinolysis involved by tissue-type plasminogen activator, as well as fibrinolysis, extracellular matrix loops, cell migration,tissue repair,tumor invasion and metastasis process involved by urokinase-- type plasminogen activator under physiological and pathological conditions.
出处 《国际呼吸杂志》 2012年第24期1890-1893,共4页 International Journal of Respiration
关键词 纤溶酶原激活物抑制物-1 肺血栓栓塞症 肺纤维化 支气管哮喘 Plasminogen activator inhibitor-1 Pulmonary thromboembolism Pulmonary fibrosis Bronchial asthma
  • 相关文献

参考文献22

  • 1Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost, 2009,101 : 656-664.
  • 2Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol,2009,5:203- 211.
  • 3Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol, 1998, 18: 84-91.
  • 4Adamski MG, Turaj W, Slowik A, et al. A C-4G haplotype of PAI-1 gene polymorphisms 844 G/A, HindIII G/C, and- 675 4G/SG is associated with increased risk of ischemic stroke caused by small vessel disease. Aeta Neurol Scand, 2009,120:94-100.
  • 5Muetze S, Eggermann T, Leeners B, et al. The 4G/5G polymorphism in the plasminogen activator inhibitor 1 gene is not associated with HELLP syndrome. J Thromb Thrombolysis, 2009,27 : 141-145.
  • 6Coulam CB, Wallis D, Weinstein J, et al. Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. Am J Reprod Immunol,2008,60:426 -431.
  • 7Ozbek OY, Atac FB, Ogus E, et al. Plasminogen activator inhibitor-1 gene 4G/SG polymorphism in Turkish children with asthma and allergic rhinitis. Allergy Asthma Proc, 2009, 30,41- 46.
  • 8Liu RM. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal, 2008,10 : 303-319.
  • 9马海玲,王献华,刘宏伟.纤溶酶原激活物抑制因子1及其在肺纤维化中的作用[J].中国煤炭工业医学杂志,2010,13(2):298-299. 被引量:2
  • 10李艳彦,翟振国,王辰.纤溶酶原激活物抑制剂1与静脉血栓栓塞性疾病[J].国际呼吸杂志,2009,29(24):1489-1492. 被引量:6

二级参考文献64

  • 1吴琦,陈永利,张敬霞,王佩显,袁志明.纤溶酶原激活物在肺血栓栓塞症发病机制中的作用[J].天津医药,2005,33(1):9-11. 被引量:9
  • 2李杨,宋良文,王德文,彭瑞云,高亚兵,马俊杰.γ射线对肺成纤维细胞中转录因子SP1,AP1和Smad3-Smad4活性的影响及意义[J].中华放射医学与防护杂志,2005,25(4):329-332. 被引量:3
  • 3翟振国,王辰,杨媛华,庞宝森,肖白,刘艳梅,毛燕玲,翁心植.纤溶酶原激活物抑制剂-1启动子区域基因多态性与肺血栓栓塞症的相关性研究[J].中华医学杂志,2006,86(19):1313-1317. 被引量:13
  • 4Tsantes AE,Nikolopoulos GK,Bagos PG, et al. The effect of the plasminogen activator inhibitor-1 4G/SG polymorphism on the thrombotic risk. Thromb Res, 2008,122 : 736-742.
  • 5Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vase Biol, 1998, 18 : 84-91.
  • 6Mlynarska A, Waszyrowski T, Kasprzak JD. Plasminogen activator inhibitor-1 (PAI-1) : pathogenetic role in coronary disease. Kardiol Pol, 2007,65 : 1109-1114.
  • 7Agren A, Wiman B, Schulman S. Low PAI-1 activity in relation to inflammatory parameters, insulin profile and body mass index. J Intern Med, 2008,264 : 586-592.
  • 8Dichtl W, Ares MP, Stollenwerk M, et al. In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element. Thromb Haemost, 2000,84 : 706-711.
  • 9Eriksson P, Nilsson L, Karpe F, et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vase Biol, 1998,18 : 20-26.
  • 10Usalan C, Buyukhatipoglu H. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytie system. Clin Appl Thromb Hemost, 2008,14 : 203- 209.

共引文献7

同被引文献80

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部